• PSS24 QUALITY OF LIFE IN OCULAR HYPERTENSION AND PRIMARY OPEN ANGLE GLAUCOMA

    Nov 1, 2010, 00:00

  • PMS38 COST-EFFECTIVENESS OF RITUXIMAB VERSUS ALTERNATIVE ANTI-TUMOR NECROSIS FACTOR (TNF) THERAPY AFTER PREVIOUS FAILURE OF ONE ANTI-TNF AGENT FOR TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO

    Nov 1, 2010, 00:00

  • PIN51 UPDATING THE COST-EFFECTIVENESS OF ROTAVIRUS VACCINATION IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PMS25 DIRECT MEDICAL COSTS OF OSTEOARTHRITIS IN SPAIN

    Nov 1, 2010, 00:00

  • PCN42 COSTS OF MANAGING ADVERSE EVENTS OF FIRST-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO- BEVACIZUMAB IN COMBINATION WITH INTERFERON-ALPHA-2A COMPARED WITH SUNITINIB

    Nov 1, 2010, 00:00

  • PIN61 INFLUENZA RISK AND VACCINATION RATES IN EUROPE- A NATIONWIDE SURVEY OF ADULTS

    Nov 1, 2010, 00:00

  • PCN10 EXPLORATIVE ANALYSIS ABOUT THE POTENTIAL OF A LARGE GPS LONGITUDINAL DATABASE ON SEARCHING CAUSAL ASSOCIATIONS AMONG PATHOLOGIES

    Nov 1, 2010, 00:00

  • PMS2 DISABILITY OUTCOMES AND DOSE ESCALATION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR BLOCKERS- A COMPARATIVE EFFECTIVENESS ANALYSIS

    Nov 1, 2010, 00:00

  • DU3 ASSESSMENT OF THE KNOWLEDGE AND PERCEPTIONS OF THE MALAYSIAN COMMUNITY PHARMACISTS REGARDING PHARMACOVIGILANCE- FINDINGS FROM AN INTERVENTIONAL STUDY

    Nov 1, 2010, 00:00

  • PIN1 SURGICAL SITE INFECTION IN CHINA- A SYSTEMATIC REVIEW OF THE INCIDENCE AND ECONOMIC BURDEN

    Nov 1, 2010, 00:00

  • PCV82 COMMUNICATING COST-EFFECTIVENSS RATIOS TO DECISION MAKERS-THE CASE OF SWEDISH NATIONAL GUIDELINES FOR HEART DISEASES

    Nov 1, 2010, 00:00

  • PSY54 THE DETERMINANTS OF HRQOL FOR PERSONS TAKING PRESCRIPTION PAIN MEDICATIONS- EVIDENCE FOR THE EUROPEAN UNION

    Nov 1, 2010, 00:00

  • PDB21 IMPACT ASSESSMENT OF CBIA-DM STRATEGY ON DIABETIC PATIENTS QUALITY OF LIFE

    Nov 1, 2010, 00:00

  • PCV142 AN APPLICATION OF IMPUTATION TECHNIQUES TO IMPROVE DATA AVAILABILITY FROM ELECTRONIC MEDICAL RECORDS

    Nov 1, 2010, 00:00

  • PMC47 FURTHER INSIGHT INTO DESIGNING WEB-BASED PATIENT REPORTED OUTCOMES FOR USE ON PERSONAL COMPUTERS IN GLOBAL STUDIES

    Nov 1, 2010, 00:00

  • PCV23 DISCONTINUATION OF LOW-DOSE ACETYLSALICYLIC ACID TREATMENT FOR SECONDARY PREVENTION OF CARDIOVASCULAR OUTCOMES- INCIDENCE AND PREDICTORS

    Nov 1, 2010, 00:00

  • PND7 ECONOMIC IMPACT OF PERSISTENCE TO DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF MULTIPLE SCLEROSIS

    Nov 1, 2010, 00:00

  • PHP9 BUDGET IMPACT ANALYSIS OF ORPHAN DRUGS IN BELGIUM- ESTIMATES FROM 2008 TO 2013

    Nov 1, 2010, 00:00

  • PDB71 QUALITY-ADJUSTED LIFE-YEAR (QALY) WEIGHTS ASSOCIATED WITH DIFFERENT SEVERITY LEVELS OF DIABETIC RETINOPATHY

    Nov 1, 2010, 00:00

  • PCV8 LOST YEARS OF LIFE DUE TO DEATH FROM PULMONARY EMBOLISM IN HOSPITALIZED PATIENTS VERIFIED BY AUTOPSY FROM 1983 TILL 2005

    Nov 1, 2010, 00:00

  • PSS28 DEVELOPMENT OF AN INSTRUMENT MIRRORING PATIENT AND PHYSICIAN PERCEPTION OF PSORIASIS SEVERITY AND TREATMENT EFFECT

    Nov 1, 2010, 00:00

  • PUK2 COMPARING THE RISK OF DEATH BETWEEN PERITONEAL DIALYSIS AND HEMODIALYSIS IN TAIWANS ESRD POPULATION

    Nov 1, 2010, 00:00

  • PND3 EFFICACY AND TOLERABILITY OF INTERFERON-BETA IN ALL TYPE OF MULTIPLE SCLEROSIS

    Nov 1, 2010, 00:00

  • PND39 RESPONSIVENESS OF THE MULTIPLE SCLEROSIS INTERNATIONAL QUALITY OF LIFE QUESTIONNAIRE TO EXPANDED DISABILITY STATUS SCALE SCORE CHANGES IN PATIENTS WITH MULTIPLE SCLEROSIS- MONTH 12 RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY

    Nov 1, 2010, 00:00

  • PCV31 BLOOD PRESSURE CONTROL AND ANTIHYPERTENSIVE STRATEGY DIFFERENCES ACCORDING TO PATIENTS AGE

    Nov 1, 2010, 00:00

  • PCN81 COST-EFFECTIVENESS ANALYSIS OF THREE STRATEGIES OF ERLOTINIB TREATMENT IN NON0-SMALL-CELL LUNG CANCER-A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC)

    Nov 1, 2010, 00:00

  • PDB78 WILLINGNESS-TO-PAY FOR DIABETES DRUG THERAPY BASED ON META-ANALYSIS RESULTS

    Nov 1, 2010, 00:00

  • PSS9 COSTS OF GLAUCOMA IN SWEDEN-A PILOT STUDY

    Nov 1, 2010, 00:00

  • PIH13 COMPLIANCE WITH HORMONE THERAPY AMONG MENOPAUSAL WOMEN AFTER THE WHI PUBLICATION IN TAIWAN

    Nov 1, 2010, 00:00

  • PSS36 ECONOMIC ANALYSIS OF CATARACT SURGERY IN EUROPE-AN ANALYSIS OF HOSPITAL DATABASES AVAILABLE IN 11 COUNTRIES

    Nov 1, 2010, 00:00

  • PMS48 PSYCHOMETRIC PROPERTIES OF THE GREEK MODIFIED HEALTH ASSESSMENT QUESTIONNAIRE FOR ASSESSING PHYSICAL DISABILITY IN RHEUMATOID ARTHRITIS

    Nov 1, 2010, 00:00

  • PMC3 A NOVEL APPROACH TO MATCHING ADJUSTED INDIRECT COMPARISON ANALYSIS USING COMMON SAS 9.2 PROCEDURES

    Nov 1, 2010, 00:00

  • PCV123 EPIDEMIOLOGICAL STUDY OF EUROPEAN CARDIOVASCULAR RISK PATIENTS- DISEASE PREVENTION AND MANAGEMENT IN USUAL DAILY PRACTICE-TURKISH RESULTS OF EURIKA STUDY

    Nov 1, 2010, 00:00

  • PCN112 PATIENT CHARACTERISTICS, MEDICATION USE, RESOURCE USE AND MEDICAL COSTS AMONG PATIENTS WITH METASTATIC PANCREATIC CANCER (MPC)

    Nov 1, 2010, 00:00

  • PRS28 ECONOMIC EVALUATION OF FLUTICASONE PROPIONATE/ SALMETEROL COMBINATION THERAPY AND MONTELUKAST IN ADULT PATIENTS WHO ARE SYMPTOMATIC ON SHORT-ACTING BETA 2-AGONIST ALONE

    Nov 1, 2010, 00:00

  • PHP116 ANALYSIS OF ANTICOAGULATION BRIDGING THERAPY IN ORTHOPEDIC PATIENTS- REAL WORLD ANALYSIS

    Nov 1, 2010, 00:00

  • PMS76 A LONGITUDINAL COMPARISON OF MAPPING EQUATIONS DERIVED FROM BASELINE AND POST-INTERVENTION DATA

    Nov 1, 2010, 00:00

  • PUK19 ECONOMIC EVALUATION OF ALISKIREN IN TYPE 2 DIABETES AND HYPERTENSION PATIENTS WITH NEPHROPATHY IN MEXICO

    Nov 1, 2010, 00:00

  • PUK21 LONG-TERM COST-EFFECTIVENESS OF SIROLIMUS BASED REGIMEN COMPARED WITH CALCINEURIN INHIBITOR BASED REGIMENS IN LOWER IMMUNOLOGICAL RISK RENAL TRANSPLANT RECIPIENTS IN KOREA

    Nov 1, 2010, 00:00

  • PHP10 USING ASSET INDEX FOR MEASURING HOUSEHOLD LIVING STANDARDS AND MONITORING HEALTH EQUITY IN THAILAND

    Nov 1, 2010, 00:00

  • PMH48 IMPACT OF ONCE-DAILY DOSING ON DRUG DISCONTINUATION OF PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2010, 00:00

  • PSS6 ASTIGMATISM AND COST OF POST-CATARACT SURGERY SPECTACLE WEAR IN KOREA

    Nov 1, 2010, 00:00

  • PDB45 COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN SPAIN

    Nov 1, 2010, 00:00

  • PMH10 COST SAVING POTENTIAL OF GENERIC SUBSTITUTION-THE CASE OF ANTIDEPRESSANTS

    Nov 1, 2010, 00:00

  • RS4 THE INFLUENCE OF UK RISK-SHARING MODELS (PATIENT ACCESS SCHEMES) ON PAYERS IN GERMANY AND THE NETHERLANDS. A QUALITATIVE RESEARCH APPROACH

    Nov 1, 2010, 00:00

  • PCV30 PREVALENCE AND CONTROL OF TRADITIONAL CARDIOVASCULAR RISK FACTORS AND ANTICIPATED AVOIDABLE CORONARY MORTALITY IN PRIMARY PREVENTION IN EUROPE-THE EURIKA STUDY

    Nov 1, 2010, 00:00

  • PHP25 DOES HUMAN MEDICINES DEVELOPMENT IN THE EUROPEAN UNION ADDRESS GLOBAL AND REGIONAL HEALTH CONCERNS?

    Nov 1, 2010, 00:00

  • PHP15 DRUG COMPARATOR DIFFERENCES IN THE THERAPEUTIC BULLETINS IN SPAIN-THE JCNDE EXPERIENCE

    Nov 1, 2010, 00:00

  • PHP37 THE IMPACT OF UNIVERSAL COVERAGE ON EQUITY IN HEALTH CARE FINANCE AND FINANCIAL RISK PROTECTION IN THAILAND

    Nov 1, 2010, 00:00

  • PHP1 ORPHAN DRUGS- DOES SOCIETY VALUE RARITY?

    Nov 1, 2010, 00:00

  • PMH17 COST OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN GERMANY

    Nov 1, 2010, 00:00

  • PCN160 THE ROLE OF PATIENT SELECTION CRITERIA IN IDENTIFYING OVARIAN CANCER PATIENTS

    Nov 1, 2010, 00:00

  • ISPOR 13TH ANNUAL EUROPEAN CONGRESS DISCLOSURE INFORMATION

    Nov 1, 2010, 00:00

  • PND26 MEDICO-ECONOMIC EVALUATION OF LACOSAMIDE ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH REFRACTORY EPILEPSY IN SCOTLAND AND SPAIN

    Nov 1, 2010, 00:00

  • PIN62 AN ECONOMIC EVALUATION OF HIBMENCY VACCINATION FOR THE PREVENTION OF HEMOPHILUS INFLUENZAE TYPE B AND NEISSERIA MENINGITIDIS TYPES C AND Y

    Nov 1, 2010, 00:00

  • PIH40 METHODOLOGICAL CONSIDERATIONS WHEN ASSESSING WORK PRODUCTIVITY (WP) AND ACTIVITIES OF DAILY LIVING (ADL) OUTCOMES IN MULTINATIONAL CLINICAL TRIALS IN WOMEN WITH HEAVY AND/OR PROLONGED MENSTRUAL BLEEDING (HPMB) TREATED WITH ESTRADIOL V ...

    Nov 1, 2010, 00:00

  • VA2 GATHERING INFORMATION BY COMPARISON OF DIFFERENT DYNAMIC MODELING APPROACHES FOR EPIDEMIC MODELS

    Nov 1, 2010, 00:00

  • PUK3 ASSESSMENT OF COMORBIDITIES IN PATIENTS WITH OVERACTIVE BLADDER (OAB) DISORDER- AN ELECTRONIC MEDICAL RECORD (EMR) DATA ANALYSIS

    Nov 1, 2010, 00:00

  • PCV138 MEASUREMENT PROPERTIES OF PEAK VO2 IN CHILDREN WITH PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2010, 00:00

  • PDB20 A PHARMACOECONOMIC MODEL FOR ADJUVANT TREATMENT IN A SMOKING CESSATION INTERVENTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2010, 00:00

  • PCV36 PRESCRIPTION PATTERN OF DUAL ANTIPLATELET THERAPY AMONG TAIWANESE OLDER ADULTS

    Nov 1, 2010, 00:00

  • PDB69 UTILITY VALUES FOR DIABETES COMPLICATIONS

    Nov 1, 2010, 00:00

  • PCV21 MODELING THE COST-EFFECTIVENESS OF CORONARY COMPUTED TOMOGRAPHY FOR PATIENTS WITH CHEST PAIN USING BOTH DIAGNOSTIC AND PROGNOSTIC INFORMATION

    Nov 1, 2010, 00:00

  • PDB61 ECONOMIC EVALUATION OF LIRAGLUTIDE VS. ROSIGLITAZONE OR EXENATIDE FOR TYPE 2 DIABETES MELLITUS IN BULGARIA

    Nov 1, 2010, 00:00

  • PHP5 PATIENT DISCHARGE FROM INTENSIVE CARE UNITS WITHIN AND BETWEEN HOSPITALS IN HUNGARY

    Nov 1, 2010, 00:00

  • PIN5 HOW LONGITUDINAL PATIENT RECORDS CAN HELP PUBLIC HEALTH AUTHORITIES IN THE MANAGEMENT OF RAPIDLY GROWING EPIDEMICS? THE EXPERIENCE OF FLU A/H1N1 IN FRANCE

    Nov 1, 2010, 00:00

  • PDB7 PREDICTORS FOR THE INITIATION OF A BASAL SUPPORTED ORAL THERAPY (BOT) IN TYPE 2 DIABETIC PATIENTS UNDER REAL-LIFE CONDITIONS IN GERMANY

    Nov 1, 2010, 00:00

  • ISPOR 13th Annual European Congress Author Index

    Nov 1, 2010, 00:00

  • PHP33 RATIONING IN PRACTICE- EQUITY IN WAITING TIMES FOR ELECTIVE SURGERY IN SWEDEN

    Nov 1, 2010, 00:00

  • PSY19 PREDICTORS OF DULOXETINE TREATMENT INITIATION AMONG PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN IN SOUTH CENTER VETERANS AFFAIRS HEALTH CARE NETWORK IN THE UNITED STATES

    Nov 1, 2010, 00:00

  • PRS40 EVALUATION OF SMOKING CESSATION DRUG USE AND OUTCOMES IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PMS35 COST-EFFECTIVENESS OF TERIPARATIDE IN PATIENTS WITH GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN SWEDEN

    Nov 1, 2010, 00:00

  • PRS1 RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS IN SPECIAL POPULATIONS

    Nov 1, 2010, 00:00

  • PCN13 EFFECT OF ZOLEDRONIC ACID AND PAMIDRONATE ON SKELETALRELATED EVENTS AND MORTALITY IN WOMEN WITH BONE METASTASES FROM BREAST CANCER IN A MANAGED CARE PLAN- A RETROSPECTIVE DATABASE ANALYSIS

    Nov 1, 2010, 00:00

  • PMC42 TO WHAT EXTENT CAN TECHNOLOGY IMPROVE THE VALIDITY OF CLINROS?

    Nov 1, 2010, 00:00

  • PSY30 ONE-YEAR-LONG TREATMENT OF FAILED BACK SURGERY SYNDROME WITH SPINAL CORD STIMULATION- COSTS AND BENEFITS IN THE ITALIAN CONTEXT (PRECISE STUDY)

    Nov 1, 2010, 00:00

  • PCV99 COMPLIANCE AND PERSISTENCE WITH ANTIHYPERTENSIVES IN THE NETHERLANDS; A COMPARATIVE ANALYSIS WITH SPECIFIC FOCUS ON RAAS INTERVENING AGENTS

    Nov 1, 2010, 00:00

  • PDB67 FACTORS INFLUENCING VALUATION OF- AND WILLINGNESS TO PARTICIPATE IN- A LIFESTYLE INTERVENTION- AN EXPLORATORY CONJOINT ANALYSIS WITH DIABETES TYPE 2 PATIENTS

    Nov 1, 2010, 00:00

  • PMH47 MEDICATION COMPLIANCE AND HEALTH CARE COSTS OF TYPE II DIABETICS WITH SCHIZOPHRENIA NEWLY STARTING HYPOGLYCEMIC THERAPY

    Nov 1, 2010, 00:00

  • PSY17 ECONOMIC OUTCOMES ASSOCIATED WITH HYDROXYUREA ADHERENCE AMONG PEDIATRIC MEDICAID ENROLLEES WITH SICKLE CELL DISEASE

    Nov 1, 2010, 00:00

  • PRS6 DEVELOPING AND APPLYING A STOCHASTIC DYNAMIC POPULATION MODEL FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2010, 00:00

  • PMS73 LINKAGE OF ADMINISTRATIVE AND MEDICAL RECORDS DATABASES FOR INVESTIGATING PHARMACEUTICAL USE AND OUTCOMES

    Nov 1, 2010, 00:00

  • PMC6 ESTIMATING EQ-5D TARIFFS FOR MALAYSIA USING TIME TRADE OFF AND VISUAL ANALOGUE SCALE

    Nov 1, 2010, 00:00

  • PCV118 TO DETERMINE THE EFFECT OF DIFFERENT DOSES OF POMEGRANATE ON BODY WEIGHT AND BLOOD PRESSURE

    Nov 1, 2010, 00:00

  • PMS62 CERTOLIZUMAB PEGOL MONOTHERAPY PROVIDES SUSTAINED IMPROVEMENTS IN HOUSEHOLD PRODUCTIVITY AND DAILY ACTIVITIES IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS OVER 2 YEARS

    Nov 1, 2010, 00:00

  • PMC24 LAST OBSERVATION CARRIED FORWARD (LOCF) VS. MIXED-EFFECTS MODEL REPEATED MEASURES (MMRM)- EMPIRICAL EVALUATION OF TWO APPROACHES TO ANALYZING LONGITUDINAL DATA WITH MISSING OBSERVATIONS

    Nov 1, 2010, 00:00

  • PCN8 IDENTIFYING KEY PROCEDURES IN HEPATOCELLULAR CARCINOMA PATIENTS WITH HIGHEST PAYER BUDGET IMPACT IN A COMMERCIALLY INSURED POPULATION IN THE UNITED STATES

    Nov 1, 2010, 00:00

  • PCN150 SYSTEMATIC LITERATURE REVIEW ON THE INTER AND INTRA LABORATORY VARIABILITY OF MOLECULAR TESTING OF RESPONSE TO TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS AND THE ASSOCIATED COSTS AND COST-EFFECTIVENESS

    Nov 1, 2010, 00:00

  • PSS22 INDIRECT COSTS OF INFORMAL CARE FOR ONE EPISODE OF ACUTE OTITIS MEDIA IN GERMANY

    Nov 1, 2010, 00:00

  • PSS11 MEDICATION CHOICE AND ASSOCIATED HEALTH-CARE OUTCOMES AND COSTS FOR PATIENTS WITH PSORIASIS IN THE UNITED STATES

    Nov 1, 2010, 00:00

  • PCV73 ECOMOMIC EVALUATION OF COMBINATION THERAPY FOR HYPERTENSION IN HIGH RISK PATIENTS IN SWEDEN

    Nov 1, 2010, 00:00

  • PCV59 COMPLIANCE INFLUENCE, PERSISTENCE AND THE BLOOD PRESSURE CONTROL GRADE ASSOCIATED WITH THE INCIDENCE OF CARDIOVASCULAR EVENTS AND THE SANITARY COSTS IN CONSUMPTION OF FIXED-DOSES IN THE ARTERIAL HYPERTENSION TREATMENT

    Nov 1, 2010, 00:00

  • PHP31 WILLINGNESS TO PAY PER QUALITY ADJUSTED LIFE-YEAR- IS ONE THRESHOLD APPLICABLE FOR ALL DECISION-MAKING?

    Nov 1, 2010, 00:00

  • PRS27 COUNTRY ADAPTATION OF A HEALTH ECONOMIC MODEL-THE CASE FOR ROFLUMILAST IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PSY53 ORGANIZATION OF ACUTE PAIN SERVICE (APS) IN THE HUNGARIAN HOSPITAL SETTING

    Nov 1, 2010, 00:00

  • PND48 MODIFIED LAST OBSERVATION CARRIED FORWARD IS A SUPERIOR METHOD OF IMPUTATION

    Nov 1, 2010, 00:00

  • PRS16 PITFALLS IN THERAPEUTIC REFERENCE PRICING PRACTICE OF THE MEDICATION OF ASTHMA

    Nov 1, 2010, 00:00

  • PCN68 COST-EFFECTIVENESS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VERSUS FILGRASTIM FOR THE PREVENTION OF FEBRILE NEUTROPENIA IN NON-HODGKIN LYMPHOMA AND STAGE II BREAST CANCER PATIENTS IN GERMANY

    Nov 1, 2010, 00:00

  • PMH53 FACTOR STRUCTURE OF A SOCIAL SUPPORT SCALE FOR ADOLESCENTS TREATED FOR SUBSTANCE USE DISORDER

    Nov 1, 2010, 00:00

  • PIH8 CHANGES IN PELVIC FLOOR MUSCLE FUNCTION DURING THE PERIOPERATIVE PERIOD OF COLPORRHAPHY

    Nov 1, 2010, 00:00

  • PHP95 THE DOS AND DONTS IN PAYER COMMUNICATION. A QUALITATIVE RESEARCH ACROSS FIVE EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PCV1 COST-EFFECTIVENESS OF ACUTE ISCHEMIC STROKE IN CHINA- MARKOV MATRIX ANALYSES

    Nov 1, 2010, 00:00

  • PMC50 TRANSLATION, LINGUISTIC VALIDATION AND ELECTRONIC ADMINISTRATION IN THE INDIAN LANGUAGES- A CASE STUDY HIGHLIGHTING THE SPECIAL DIFFICULTIES THAT EXIST AT THIS INTERSECTION

    Nov 1, 2010, 00:00

  • PMH14 COST ANALYSIS OF ADVERSE EVENTS ASSOCIATED WITH TREATMENT OF BIPOLAR DISORDER- A COMPARISON BETWEEN ARIPIPRAZOLE AND OLANZAPINE IN THE SPANISH HEALTH SYSTEM

    Nov 1, 2010, 00:00

  • PHP20 QUALITY ASSURANCE OF FOURTH HURDLE CONCERNING TO MEDICAL DEVICES

    Nov 1, 2010, 00:00

  • PHP64 VALUE BASED PRICING IN THE UK-A PRICE-QUANTITY MODEL ASSESSMENT

    Nov 1, 2010, 00:00

  • PSS17 ECONOMIC EVALUATION OF A 100-WHEY BASED PARTIALLY HYDROLYZED FORMULA IN THE PREVENTION OF ATOPIC DERMATITIS AMONG DANISH CHILDREN- PRELIMINARY ANALYSES

    Nov 1, 2010, 00:00

  • PIH3 PARENTERAL ALANYL-GLUTAMMINE IN CRITICALLY ILL PATIENTS- A BAYESIAN META-ANALYSIS OF PUBLISHED TRIALS

    Nov 1, 2010, 00:00

  • PSS14 PHARMACOECONOMICS OF INNOVATIVE MEDICINES FOR TREATMENT OF PSORIASIS IN UKRAINE

    Nov 1, 2010, 00:00

  • PND8 THE POTENTIAL COST IMPACT OF USING A PEG HYDROGEL SEALANT COMPARED WITH FIBRIN SEALANT TO PREVENT CEREBRAL SPINAL FLUID LEAKS AFTER CRANIAL SURGERY IN THE UK

    Nov 1, 2010, 00:00

  • PSY45 PREGABALIN IS A COST-EFFECTIVE MEDICINE FOR REFRACTORY NEUROPATHIC PAIN IN SWEDEN

    Nov 1, 2010, 00:00

  • PMS5 MICRO-COSTING OF JUDO-THERAPY CLINICS IN JAPAN-MULTI CENTERED COST ANALYSIS

    Nov 1, 2010, 00:00

  • DU4 COST-EFFECTIVENESS ANALYSIS OF TRAVOPROST FOLLOWED BY FIXED COMBINATION TRAVOPROST/TIMOLOL TREATMENT SEQUENCE (T-TTFC) COMPARED TO LATANOPROST FOLLOWED BY LATANOPROST/TIMOLOL FIXED COMBINATION (L-LTFC) FOR PATIENTS WITH OPEN ANGLE GLAUC ...

    Nov 1, 2010, 00:00

  • PDB16 DEVELOPMENT OF A THAI VERSION OF THE AUDIT OF DIABETESDEPENDENT QUALITY OF LIFE (ADDQOL-19) QUESTIONNAIRE- LINGUISTIC AND PSYCHOMETRIC EVALUATION

    Nov 1, 2010, 00:00

  • PGI12 ECONOMIC CONSEQUENCES OF POORLY CONTROLLED PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE IN GERMANY, ITALY AND SPAIN

    Nov 1, 2010, 00:00

  • PHP100 EVALUATION OF ACCEPTANCE AND REJECTION RATES OF ORPHAN DRUGS ACROSS SIX HTA AGENCIES

    Nov 1, 2010, 00:00

  • PDB16 INSULIN GLARGINE IS ASSOCIATED WITH A LOWER INCIDENCE OF DIABETIC FOOT SYNDROME AND MACROVASCULAR COMPLICATIONS COMPARED TO NPH INSULIN IN TYPE 2 DIABETICS UNDER GERMAN REAL-LIFE CONDITIONS

    Nov 1, 2010, 00:00

  • PIH58 HEALTH AND ECONOMY- A GOVERNMENTAL PERSPECTIVE, NATIONAL ACCOUNTING MODEL FOR ASSESSING INVESTMENTS IN ROTAVIRUS VACCINATION

    Nov 1, 2010, 00:00

  • PDB1 CLINICAL OUTCOMES WITH DPP4 INHIBITORS IN SINGAPORE

    Nov 1, 2010, 00:00

  • PHP128 THE USE OF HEALTH PROMOTION INITIATIVES BY MUNICIPALITIES IN BELGIUM. A RETROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2010, 00:00

  • PMH51 HEALTH STATUS AND COST OF CARE IN PATIENTS WITH DEMENTIA IN GERMANY

    Nov 1, 2010, 00:00

  • PMS8 OCCURRENCE OF SECUNDARY HIP AND FEMUR FRACTURES ACCORDING TO RISK FACTORS FOLLOW-UP 8 YEARS

    Nov 1, 2010, 00:00

  • PIH37 RELATIONSHIP BETWEEN HEALTH-CARE PROFESSIONALS ND POPULATION HEALTH STATUS- DO NUMBERS COUNT?

    Nov 1, 2010, 00:00

  • HT1 REAL-WORLD DATA-IMPROVING APPROACHES FOR DEMONSTRATING BENEFITS AND RISKS OF NEW DRUGS

    Nov 1, 2010, 00:00

  • PIH2 IMPACT OF HPV VACCINATION ON CERVICAL CANCER IN ASIA- RESULTS OF A STATIC MODEL

    Nov 1, 2010, 00:00

  • PUK34 PSYCHOMETRIC VALIDATION OF THE SPANISH VERSION OF THE TREATMENT BENEFIT SCALE (TBS) FOR ASSESSING SUBJECTIVE OUTCOMES IN TREATING PATIENTS WITH OVERACTIVE BLADDER

    Nov 1, 2010, 00:00

  • PIN25 SEASONAL INFLUENZA VACCINATION OF HEALTHY, WORKING-AGE ADULTS- A SYSTEMATIC REVIEW OF ECONOMIC INVESTIGATIONS

    Nov 1, 2010, 00:00

  • PCV26 AN EPIDEMIOLOGICAL EVALUATION OF THE INCIDENCE OF DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN PATIENTS WITH HIP OR KNEE REPLACEMENT SURGERY AND OF ITS IMPACT ON THE AVERAGE LENGTH OF STAY

    Nov 1, 2010, 00:00

  • PRS9 DRUG UTILIZATION EVALUATION OF COMBINED INHALER THERAPIES AMONG PATIENTS WITH AIRWAY DISEASES IN A 2000-BED MEDICAL CENTER IN TAIWAN

    Nov 1, 2010, 00:00

  • ISPOR 4th Asia-Pacific Conference Author Index

    Nov 1, 2010, 00:00

  • PCV134 THERAPEUTIC VERSUS ACTUAL MARKET SHARES FOR STATINS

    Nov 1, 2010, 00:00

  • PCV77 A SIMULATION MODEL TO ASSESS COST-EFFECTIVENESS OF STATINS IN HIGH RISK PATIENTS WITH ELEVATED LDL-C IN SPAIN

    Nov 1, 2010, 00:00

  • PCN1 TOLERABILITY OF FIRST-LINE TREATMENTS OF LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC)-A SYSTEMATIC REVIEW AND ADJUSTED INDIRECT COMPARISON

    Nov 1, 2010, 00:00

  • PCV40 CLINICAL AND ECONOMIC IMPACT OF USE OF A POCKET-SIZED ULTRASOUND DEVICE FOR HEART FAILURE HOSPITALIZATIONS IN ITALY

    Nov 1, 2010, 00:00

  • PSS1 EPIDEMIOLOGY AND COMORBIDITIES OF PATIENTS WITH PSORIASIS N TAIWAN

    Nov 1, 2010, 00:00

  • PCV132 AN INTERNATIONAL COMPARISON OF ANTIPLATELET USE AT 6 MONTHS FOLLOWING HOSPITAL DISCHARGE IN UA/NSTEMI AND STEMI PATIENTS UNDERGOING PCI- RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL REGISTRY II (APTOR-II)

    Nov 1, 2010, 00:00

  • PCV35 THE BUDGET IMPACT ANALYSIS OF AMBRISENTAN IN 2ND LINE TREATMENT OF ADULT PATIENTS WITH IDIOPATHIC, FAMILIAR OR ASSOCIATED WITH CONNECTIVE TISSUE DISEASE PULMONARY HYPERTENSION OF III NYHA STAGE

    Nov 1, 2010, 00:00

  • PIN38 AN ECONOMIC EVALUATION OF THE PEDIATRIC VACCINATION SCHEDULE IN THE UNITED STATES

    Nov 1, 2010, 00:00

  • PRS46 ADJUSTING FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) SEVERITY IN DATABASE RESEARCH- FEASIBILITY OF DEVELOPING AND VALIDATING AN ALGORITHM

    Nov 1, 2010, 00:00

  • PIN29 A DYNAMIC MODEL TO EVALUATE THE COST-EFFECTIVENESS OF 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN TAIWAN

    Nov 1, 2010, 00:00

  • PMH46 ADHERENCE RATES OF INJECTABLE VS. ORAL RISPERIDONE FOR PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2010, 00:00

  • PHP57 AN ANALYSIS OF DRUG COST CONTAINMENT POLICY AT A HOSPITAL IN SOUTHERN THAILAND

    Nov 1, 2010, 00:00

  • PDB11 CLINICAL AND COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 ONCE OR TWICE DAILY VERSUS INSULIN GLARGINE IN TYPE 2 DIABETES MELLITUS- A MODELING ANALYSIS IN THE CHINESE SETTING

    Nov 1, 2010, 00:00

  • PCV125 PROTEIN-C-REACTIVE AS A MARKER OF INFLAMMATION AND CARDIOVASCULAR DISEASE IN PATIENTS WITH SCHIZOPHRENIA-A CROSS-SECTIONAL ANALYSIS OF A HEALTH CARE PROVIDER ADMINISTRATIVE CLAIM DATABASE

    Nov 1, 2010, 00:00

  • PCN19 SYSTEMATIC REVIEW OF ENDOSCOPIC SUBMUCOSAL DISSECTION VERSUS ENDOSCOPIC MUCOSAL RESECTION FOR EARLY GASTRIC CANCER

    Nov 1, 2010, 00:00

  • PCV15 DIRECT MEDICAL COSTS FOR PULMONARY EMBOLISM AFTER ORTHOPEDIC SURGERY IN SLOVAKIA

    Nov 1, 2010, 00:00

  • PIH31 STATIC AND DYNAMIC BALANCE EXAMINATION ON STABILOMETER DURING PREGNANCY

    Nov 1, 2010, 00:00

  • PND17 MEMANTINE DELAYS THE ADMISSION OF ALZHEIMERS DISEASE PATIENTS TO NURSING HOME- COST-EFFECTIVENESS ANALYSIS IN FRANCE

    Nov 1, 2010, 00:00

  • PSY66 WEB VERSUS FACE-TO-FACE (FTF) ADMINISTRATION OF A HEALTH UTILITY SURVEY IN THE GENERAL PUBLIC- RESULTS FROM A TIME TRADE-OFF (TTO) SURVEY ON IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

    Nov 1, 2010, 00:00

  • PMH1 THE EFFICACY OF DONEPEZIL AND MEMANTINE FOR TREATING BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD) IN PATIENTS WITH ALZHEIMERS DISEASE- SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2010, 00:00

  • PSY38 COST-EFFECTIVENESS OF GOLIMUMAB IN ANKYLOSING SPONDYLITIS FROM THE UK PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • PDB56 PHARMACOECONOMIC CONSEQUENCES OF LOSARTAN THERAPY IN PATIENTS UNDERGOING DIABETIC END-STAGE RENAL DISEASE IN EU AND USA

    Nov 1, 2010, 00:00

  • HE4 THE EFFECT OF PRICE CONTAINMENT ON THE TREND OF PHARMACEUTICAL EXPENDITURE FROM 1999 TO 2007 IN TAIWAN

    Nov 1, 2010, 00:00

  • PSY29 DARBEPOETIN ALFA VERSUS EPOETIN ALFA FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA-A HEALTH ECONOMIC EVALUATION

    Nov 1, 2010, 00:00

  • PCV56 RENAL MORBIDITY, MORTALITY, AND COSTS IN INDIVIDUALS UNDERGOING INVASIVE CARDIAC CATHETERIZATION PROCEDURES WITH LOW-OSMOLAR CONTRAST MEDIA-A LARGE RETROSPECTIVE DATABASE ANALYSIS

    Nov 1, 2010, 00:00

  • PHP79 REFINING INPATIENT PSYCHIATRIC FACILITY REIMBURSEMENT- LESSONS FROM OTHER MEDICARE PROSPECTIVE PAYMENT SYSTEMS

    Nov 1, 2010, 00:00

  • PCV14 COSTS OF INITIAL ISCHEMIC STROKE CARE

    Nov 1, 2010, 00:00

  • PUK8 BUDGET IMPACT ANALYSIS OF ALISKIRENO IN TYPE 2 DIABETES PATIENTS WITH HYPERTENSION AND NEPHROPATHY IN THE MEXICAN INSTITUTE OF SOCIAL SECURITY

    Nov 1, 2010, 00:00

  • PCN39 TREATMENT PATTERNS AMONG PATIENTS WITH ADVANCED MELANOMA-A RETROSPECTIVE LONGITUDINAL STUDY

    Nov 1, 2010, 00:00

  • PHP58 ANNUAL HEALTH INSURANCE REIMBURSEMENT OF DENTAL CARE IN HUNGARY

    Nov 1, 2010, 00:00

  • PCN127 MINIMAL CLINICALLY MEANINGFUL DIFFERENCES FOR THE EORTC QLQ-C30 AND EORTC QLQ-BN20 SCALES IN BRAIN CANCER PATIENTS

    Nov 1, 2010, 00:00

  • PDB58 PHARMACOEPIDEMIOLOGICAL ASSAY AND COST-MINIMIZATION ANALYSIS OF ORAL ANTIDIABETIC MEDICATIONS AND INSULINS IN LITHUANIA

    Nov 1, 2010, 00:00

  • PIH6 BUDGET IMPACT ANALYSIS OF INCLUDING LIVER TRANSPLANTATION IN CHILDREN INTO THE UNIVERSAL COVERAGE BENEFIT PACKAGE OF THAILAND

    Nov 1, 2010, 00:00

  • PCV2 ESTIMATION OF ADVERSE EVENTS IN 3 MONTHS AFTER VENOUS THROMBOEMBOLISM EVENT FOR MEDICARE PATIENTS WHO UNDERWENT HIP FRACTURE SURGERY

    Nov 1, 2010, 00:00

  • PMS69 ECONOMY OF NSAIDS IN THE MANAGEMENT OF OSTEOARTHRITIS- SODIUM CHONDROITIN SULFATE VS. CONTROL GROUP

    Nov 1, 2010, 00:00

  • PDB15 HEALTH STATUS, HEALTH-RELATED QUALITY OF LIFE AND TREATMENT SATISFACTION AMONG PATIENTS WITH DIABETES IN THAILAND

    Nov 1, 2010, 00:00

  • PR4 GLOBAL MARKET ACCESS STRATEGY-AN INTEGRATED APPROACH

    Nov 1, 2010, 00:00

  • PUK7 QUALITY OF LIFE OF MALAYSIAN DIALYSIS PATIENTS ON TRANSPLANT WAITING LIST

    Nov 1, 2010, 00:00

  • PHP21 WHAT ARE THE TOP MOST COSTLY DISEASES FOR USA? THE ALIGNMENT OF BURDEN OF ILLNESS WITH PREVENTION AND SCREENING EXPENDITURES

    Nov 1, 2010, 00:00

  • PSS35 COST COMPARISON OF PATIENTS WITH CHRONIC HAND ECZEMA COVERED BY STATUTORY VS. OCCUPATIONAL HEALTH INSURANCES IN GERMANY

    Nov 1, 2010, 00:00

  • PMC27 VALUES FOR HEALTH STATES UNDER DIFFERENT LIFE DURATIONS

    Nov 1, 2010, 00:00

  • PIN10 A SYSTEMATIC REVIEW OF THE ATTRIBUTION OF HUMAN PAPILLOMAVIRUS TYPES AMONG CERVICAL INTRAEPITHELIAL NEOPLASIA AND CERVICAL CANCERS IN JAPAN BY SAMPLING METHODS

    Nov 1, 2010, 00:00

  • PHP84 A PROPOSAL FOR CLASSIFICATION OF PUBLIC FUNDING RESTRICTIONS

    Nov 1, 2010, 00:00

  • PHP34 THE EVALUATION OF HEALTH-CARE SYSTEMS OF CHINA, HONG KONG, VIETNAM, THAILAND, MALAYSIA, SINGAPORE AND AUSTRALIA

    Nov 1, 2010, 00:00

  • PGI2 IS THERE ANY DIFFERENCE BETWEEN THE EFFECTS OF THERAPY WITH PEGINTERFERON-ALPHA-2A VERSUS STANDARD-DOSE PEGINTERFERON-ALPHA-2B? A META-ANALYSIS COMPARING BOTH TREATMENTS PLUS RIBAVIRIN IN GENOTYPE 1/4 CHRONIC HEPATITIS C VIRUS (HCV) IN ...

    Nov 1, 2010, 00:00

  • PDB22 COST STUDY OF SELF-MONITORING BLOOD GLUCOSE THROUGH GLUCOMETERS IN PATIENTS WITH DIABETES MELLITUS II IN SPAIN

    Nov 1, 2010, 00:00

  • PMH7 FACTORS ASSOCIATED WITH TOTAL TIME AND COST OF PROVIDING CARE FOR THAI PATIENTS WITH DEMENTIA

    Nov 1, 2010, 00:00

  • PCN11 PREVENTION OF OXALIPLATIN HYPERSENSITIVITY REACTION AND COST SAVING

    Nov 1, 2010, 00:00

  • PMH5 ESTABLISHING THE COMPARATIVE EFFICACY OF ALZHEIMERS DISEASE THERAPY THROUGH SYSTEMATIC REVIEW AND COMPARATIVE ANALYSIS

    Nov 1, 2010, 00:00

  • PSS14 WHAT COST OF HLA-B5801 GENOTYPING WOULD BE COST EFECTIVE FOR THE PREVENTION OF ALLOPURINOL-INDUCED STEVENS JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS IN THAILAND- ANALYSES USING A DECISION-ANALYTIC MODEL

    Nov 1, 2010, 00:00

  • PMS36 COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE MANAGEMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE PREVIOUS DMARD THERAPY IN COSTA RICA

    Nov 1, 2010, 00:00

  • PSS25 MAPPING THE IMPACT OF DRY EYE ON EVERYDAY LIFE (IDEEL) QUESTIONNAIRE TO A PREFERENCE BASED UTILITY INDEX

    Nov 1, 2010, 00:00

  • PMS53 QUALITY OF LIFE, PATIENTS PREFERENCES AND INFORMED DECISION IN TREATING RHEUMATOID ARTHRITIS IN GREECE

    Nov 1, 2010, 00:00

  • PHP53 COST ANALYSIS OF ANKARA UNIVERSITY SCHOOL OF MEDICINE HOSPITALS

    Nov 1, 2010, 00:00

  • PRS17 COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE-A HEALTH CARE ADMINISTRATIVE DATABASES ANALYSIS

    Nov 1, 2010, 00:00

  • PCN99 COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE- CANADIAN PERSPECTIVE

    Nov 1, 2010, 00:00

  • PMH15 THE VALIDATION OF TWO MEASURES ASSESSING REASONS FOR ANTIPSYCHOTIC DISCONTINUATION AND CONTINUATION FROM PATIENTS PERSPECTIVES

    Nov 1, 2010, 00:00

  • PHP3 RARE DISEASES, ORPHAN DRUGS, AND THE LEGISLATION IN CHINA

    Nov 1, 2010, 00:00

  • PSY33 EARLY STAGE ECONOMIC EVALUATION OF PHARMACOGENOMICBASED DIAGNOSTICS IN CHRONIC MYELOID LEUKEMIA

    Nov 1, 2010, 00:00

  • PCV89 COST-EFFECTIVENESS OF DRONEDARONE FOR THE TREATMENT OF ATRIAL FIBRILLATION IN THE UK

    Nov 1, 2010, 00:00

  • PCN58 SURVEY AND ANALYSIS OF THE COSTS OF METASTATIC COLORECTAL CANCER TREATMENT IN BULGARIA

    Nov 1, 2010, 00:00

  • PMS6 HEALTH-CARE RESOURCE UTILIZATION AND OUTCOMES ANALYSIS OF OSTEOPOROTIC HIP FRACTURES AMONG THAI POST MENOPAUSAL WOMEN-A PILOT INVESTIGATION

    Nov 1, 2010, 00:00

  • PCV18 ECONOMIC EVALUATION OF USING HIGH-DOSE ATORVASTATIN FOR THE PREVENTION OF RECURRENT STROKE- EVIDENCE FROM THAILAND

    Nov 1, 2010, 00:00

  • PIN22 A NOVEL APPROACH FOR ESTIMATING THE VALUE OF ENTECAVIR THERAPY FOR NUCLEOSIDE-NAVE CHRONIC HEPATITIS B PATIENTS IN SPAIN

    Nov 1, 2010, 00:00

  • PMH26 COST ANALYSIS OF METHADONE MAINTENANCE THERAPY (MMT) PROGRAM IN MALAYSIA

    Nov 1, 2010, 00:00

  • PMH3 A MULTILEVEL ANALYSIS OF AREA AND INDIVIDUAL EFFECTS ON METHADONE MAINTENANCE TREATMENT IN TAIWAN

    Nov 1, 2010, 00:00

  • PCV95 ECONOMIC EVALUATION OF LIFESTYLE INTERVENTION IN PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN 60-YEAR-OLD MEN IN STOCKHOLM, SWEDEN

    Nov 1, 2010, 00:00

  • PIN3 SURGICAL SITE INFECTION IN AUSTRALIA- A SYSTEMATIC REVIEW OF THE INCIDENCE AND ECONOMIC BURDEN

    Nov 1, 2010, 00:00

  • PCN97 A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB ) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)

    Nov 1, 2010, 00:00

  • VA3 FACTORS INFLUENCING THE DECISION TO BE VACCINATED AGAINST H1N1 IN GREECE

    Nov 1, 2010, 00:00

  • PMC48 UPDATES AND INNOVATIONS IN ELECTRONIC PATIENT-REPORTED DATA CAPTURE-A REVIEW OF THE EVOLUTION AND FUTURE DIRECTIONS OF EPRO

    Nov 1, 2010, 00:00

  • PCN49 PREDICTORS OF THE DIRECT COSTS OF BREAST CANCER IN THE UNITED STATES ELDERLY POPULATION

    Nov 1, 2010, 00:00

  • PGI17 COULD AN INNOVATIVE SURGICAL PROCEDURE SUCH AS STAPLED HEMORRHOIDOPEXY BE COST-EFFECTIVE AND EVEN COST-SAVING IN UK CLINICAL PRACTICE?

    Nov 1, 2010, 00:00

  • PHP23 HEALTH DECENTRALIZATION, GOVERNMENT HEALTH EXPENDITURE AND HEALTH OUTCOME IN CHINA

    Nov 1, 2010, 00:00

  • PND16 MODELING THE CLINICAL AND ECONOMIC IMPLICATIONS OF GALANTAMINE IN THE TREATMENT OF MILD TO MODERATE ALZHEIMERS DISEASE IN GERMANY

    Nov 1, 2010, 00:00

  • PIH23 A REVIEW OF POSITIVE LIST SYSTEM IN KOREA-ACHIEVEMENTS, CHALLENGES AND SUGGESTIONS

    Nov 1, 2010, 00:00

  • PND46 NON-LOCAL PATIENT-LEVEL DATA FOR COST-EFFECTIVENESS ADAPTATION TO THE SWEDISH ENVIRONMENT

    Nov 1, 2010, 00:00

  • PRS42 EFFECTS OF ASTHMA MANAGEMENT, SOCIOECONOMIC STATUS AND MEDICATION INSURANCE CHARACTERISTICS ON EXACERBATION FREQUENCY IN CHILDREN WITH ASTHMA

    Nov 1, 2010, 00:00

  • PCV25 PATTERN OF LIPID MODIFYING AGENTS PRESCRIPTION AMONG CLUSTERS OF PHYSICIAN IN A THAI TEACHING HOSPITAL, FISCAL YEAR 2009

    Nov 1, 2010, 00:00

  • PMS49 PSYCHOMETRIC PROPERTIES OF THE RHEUMATOID ARTHRITIS DISEASE ACTIVITY INDEX (RADAI) IN A COMMUNITY POPULATION IN THE US

    Nov 1, 2010, 00:00

  • PDB9 LONG-TERM CLINICAL OUTCOMES OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE 2 DIABETES PROJECTED USING THE CORE DIABETES MODEL

    Nov 1, 2010, 00:00

  • NI2 PATIENT ACCESS SCHEMES IN UK ARE DRIVEN BY HEALTH TECHNOLOGY ASSESMENT

    Nov 1, 2010, 00:00

  • PHP90 THE EFFECT OF THE 2007 HOSPITAL REFORM ON THE NUMBER OF PSYCHIATRIC BEDS IN HUNGARY

    Nov 1, 2010, 00:00

  • PRS10 RACE AND ETHNICITY IN EMERGENCY ROOM AND NON-URGENT CARE VISITS AMONG LATINO CHILDREN SUFFERING FROM ASTHMA

    Nov 1, 2010, 00:00

  • PMS4 BURDEN OF DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CHINA- RESULTS FROM 2009 NATIONAL HEALTH AND WELLNESS SURVEY

    Nov 1, 2010, 00:00

  • PMC31 CONSTRUCTION OF PRIMARY HUI3 PERSON-MEAN UTILITY SCORING FUNCTION

    Nov 1, 2010, 00:00

  • PCV85 PRASUGREL VS. CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION- A SPANISH MODEL-BASED COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2010, 00:00

  • PCN138 HEALTH-CARE COSTS ASSOCIATED WITH BREAST CANCER MANAGEMENT

    Nov 1, 2010, 00:00

  • PHP70 CURRENT TRENDS IN HEALTH TECHNOLOGY INCORPORATION (HTI) IN BRAZIL- INSIDE THE NATIONAL HEALTH SYSTEMS (NHS) BLACK BOX

    Nov 1, 2010, 00:00

  • PGI4 BUDGET IMPACT ANALYSIS OF ORAL ANTIVIRAL AGENTS FOR THE TREATMENT OF CHRONIC HPATITIS B IN SOUTH KOREA

    Nov 1, 2010, 00:00

  • PCN38 INFLUENCE OF ME-TOOS TO POSSIBLE SAVINGS DUE TO BIOSIMILARS

    Nov 1, 2010, 00:00

  • PMH4 A PHASE IV STUDY OF THE EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE 600 MG ONCE A DAY TO CONTROL THE SYMPTOMS OF MANIC PHASE OF BIPOLAR DISORDER-THE EMMY TRIAL

    Nov 1, 2010, 00:00

  • PSS3 THE ECONOMIC BURDENS FOR PATIENTS WITH PSORIASIS IN TAIWAN

    Nov 1, 2010, 00:00

  • PMS11 HEALTH-CARE UTILIZATION OF PATIENTS WITH LOW BACK PAIN IN SOUTH KOREA (2006-2008)

    Nov 1, 2010, 00:00

  • PCN41 ECONOMIC OUTCOMES AMONG 2ND LINE NON-SMALL CELL LUNG CANCER PATIENTS IN THE OUTPATIENT COMMUNITY SETTING

    Nov 1, 2010, 00:00

  • PCN76 A SIMULATION MODELLING APPROACH TO QUANTIFY THE COST-EFFECTIVENESS OF EXTRA-CORPOREAL PHOTOPHERESIS IN CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) IN SPAIN

    Nov 1, 2010, 00:00

  • PIN8 CLINICAL EFFECTIVENESS OF THE SEASONAL INFLUENZA VACCINE IN HEALTHY INDIAN CHILDREN

    Nov 1, 2010, 00:00

  • PHP125 TRENDS IN UK-BASED PATIENT ACCESS SCHEMES- FINANCIAL-BASED VERSUS OUTCOMES-BASED AGREEMENTS

    Nov 1, 2010, 00:00

  • PGI28 HEALTH-RELATED QUALITY OF LIFE IN OPIOID INDUCED CONSTIPATION PATIENTS IN SPAIN

    Nov 1, 2010, 00:00

  • PSY46 INDIRECT COSTS OF MODERATE AND SEVERE FORMS OF PSORIASIS IN CZECH REPUBLIC- CALCULATION BASED ON SELF REPORTED QUESTIONNAIRE

    Nov 1, 2010, 00:00

  • PSY15 CONSTIPATION RELATED TO OPIOID THERAPY-A COST-OF-ILLNESS AND PREVALENCE DATABASE STUDY IN THE BRAZILIAN PRIVATE SETTING

    Nov 1, 2010, 00:00

  • PHP111 PREDICTING PREVENTIVE CARE SERVICE UTILIZATION IN A UNITED STATES POPULATION

    Nov 1, 2010, 00:00

  • PHP54 BUDGET IMPACT OF ORPHAN DRUGS IN DENMARK COMPARED TO OTHER EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PDB68 HEALTH RELATED QUALITY OF LIFE (HRQL) AND EQ-5D UTILITIES IN A TYPE 2 DIABETES (T2D) POPULATION- RESULTS FROM A SWEDISH SURVEY

    Nov 1, 2010, 00:00

  • MO4 USING AHP WEIGHTS TO FILL MISSING GAPS IN MARKOV DECISION MODELS

    Nov 1, 2010, 00:00

  • PIH18 QUALITY OF LIFE IN THAI WOMEN DIAGNOSED WITH GENITAL WARTS, CERVICAL CANCER, AND CERVICAL INTRAEPITHELIAL NEOPLASIA AT KING CHULALONGKORN MEMORIAL HOSPITAL

    Nov 1, 2010, 00:00

  • PIH26 MEDICATION CHECKUPS BY COMMUNITY PHARMACISTS- EXPERIENCE OF 'BROWN-BAG' REVIEWS IN JAPAN

    Nov 1, 2010, 00:00

  • PRS14 THE POTENTIAL COST IMPACT OF USING A PEG HYDROGEL SEALANT TO PREVENT AIR LEAKS AFTER LUNG RESECTION SURGERY IN SPAIN

    Nov 1, 2010, 00:00

  • AD1 SHORT MESSAGE SERVICE (SMS)-BASED STRATEGY TO IMPROVE ANTIPSYCHOTIC ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2010, 00:00

  • PCN167 INFORMING THE DECISION- IMPROVING GENERALIZABILITY BY PARAMETERIZING RELEVANT INFORMATION IN THE ECONOMIC EVALUATION OF TRASTUZUMAB IN EARLY BREAST CANCER

    Nov 1, 2010, 00:00

  • PCN70 COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN BRAZIL

    Nov 1, 2010, 00:00

  • PIH34 CONTENT VALIDITY OF THE BENIGN PROSTATIC HYPERPLASIA IMPACT INDEX (BII)- RESULTS FROM CONCEPT ELICITATION AND COGNITIVE INTERVIEWS

    Nov 1, 2010, 00:00

  • PUK32 CONTENT VALIDITY OF A PATIENT-REPORTED URINARY URGENCY RATING SCALE- RESULTS OF A COGNITIVE INTERVIEW STUDY

    Nov 1, 2010, 00:00

  • PRS12 THE COST ANALYSIS OF BRONCHODILATOR PRESCRIPTIONS FOR TREATMENT OF STABLE COPD IN UKRAINE

    Nov 1, 2010, 00:00

  • PIH44 THE INFLUENCE OF INDIVIDUAL FACTORS ON PELVIC PAIN AND QUALITY OF LIFE IN ENDOMETRIOSIS

    Nov 1, 2010, 00:00

  • PHP98 COST-EFFECTIVENESS METHODOLOGIES OF STRATEGIES THAT AIM TO CHANGE THE BEHAVIOUR OF HEALTH CARE PROFESSIONALS

    Nov 1, 2010, 00:00

  • PDB42 INCRETIN-THERAPY IN ADDITION TO METFORMIN AND/OR SULFONYLUREA FOR TYPE 2 DIABETES MELLITUS (T2DM)- COSTEFFECTIVENESS OF LIRAGLUTIDE VERSUS EXENATIDE FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)

    Nov 1, 2010, 00:00

  • PCN136 QUALITY OF LIFE AFTER CHEMOTHERAPY IN BREAST CANCER-A STUDY IN SOUTH OF IRAN

    Nov 1, 2010, 00:00

  • PHP133 PERSONALIZED PHARMACOTHERAPY AND ANALYSIS OF EXTEMPORANEOUS DOSAGE FORMS FOR CHILDREN IN UKRAINE

    Nov 1, 2010, 00:00

  • VA1 ARE THE BENEFITS OF FLU VACCINATION IN THE ELDERLY CORRECTLY SIMULATED IN ECONOMIC ASSESSMENT MODELS?

    Nov 1, 2010, 00:00

  • PCV13 CAN WE REDUCE COST OF ILLNESS WITH MORE COMPLIANT PATIENTS? THE ESTIMATION OF EFFECT OF 100 COMPLIANT TO TREATMENTS OF DIABETES AND HYPERTENSION

    Nov 1, 2010, 00:00

  • PIN49 COST-EFFECTIVENESS OF PEGINTERFERON ALPHA-2A PLUS RIBAVIRIN FOR TREATING CRONIC HEPATITIS C VIRUS INFECTION COMPARED WITH NO TREATMENT IN MEXICO

    Nov 1, 2010, 00:00

  • PSS15 COST-EFFECTIVENESS OF USTEKINUMAB VS. INFLIXIMAB FOR SEVERE PSORIASIS

    Nov 1, 2010, 00:00

  • PMC28 CLINICIAN REPORTED OUTCOMES- ISSUES IN THE TRANSLATION AND LINGUISTIC VALIDATION

    Nov 1, 2010, 00:00

  • PCN33 USING DISCRETE CHOICE EXPERIMENTS TO ESTIMATE THE WILLINGNESS TO PAY FOR CANCER TREATMENT IN KOREA- A GENERAL POPULATION STUDY

    Nov 1, 2010, 00:00

  • PMH66 PREVALENCE OF AFFECTIVE DISORDERS IN SOUTH-WEST REGION OF SWEDEN

    Nov 1, 2010, 00:00

  • PIH4 COST OF PUBLIC HEALTH DELIVERY OF CHILDHOOD IMMUNIZATIONS IN NOVA SCOTIA

    Nov 1, 2010, 00:00

  • PCV91 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK-A SWEDISH ECONOMIC EVALUATION OF THE JUPITER TRIAL

    Nov 1, 2010, 00:00

  • PUK6 EVALUATION OF PSYCHOMETRIC PROPERTIES OF THE JAPANESE VERSION OF THE NOCTURIA QUALITY OF LIFE QUASTIONNAIRE (N-QOL)

    Nov 1, 2010, 00:00

  • DS1 ESTIMATING ADHERENCE AND PERSISTENCY OF ANTIDEPRESSANTS USING THE KOREA NATIONAL HEALTH INSURANCE CLAIMS DATABASE

    Nov 1, 2010, 00:00

  • PDB3 EFFECTS OF EXTENDED-RELEASE VERSUS IMMEDIATE-RELEASE GLIPIZIDES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2010, 00:00

  • PCN144 CURRENT CHEMOTHERAPY AND MONOCLONAL ANTIBODY USE PATTERNS IN METASTATIC COLORECTAL CANCER IN WESTERN EUROPE

    Nov 1, 2010, 00:00

  • IR1 METHODS FOR PSYCHOMETRIC AND CLINICAL EVALUATIONS OF CAT-BASED MEASURES OF DISEASE IMPACT IN CHRONIC KIDNEY DISEASE (CKD)

    Nov 1, 2010, 00:00

  • PSY55 QUALITY OF LIFE OF OVERWEIGHT AND OBESE PATIENTS SEEKING CARE AT A PHARMACEUTICAL CARE SERVICE IN VENEZUELA

    Nov 1, 2010, 00:00

  • PCN12 COST-EFFECTIVENESS OF THE ONCOTYPE DX ASSAY IN AUSTRALIA- AN EXPLORATORY ANALYSIS

    Nov 1, 2010, 00:00

  • PGI13 MODELING THE LONG TERM CONSEQUENCES OF SUPPRESSING VIRAL REPLICATION IN CHRONIC HEPATITIS B- A COSTEFFECTIVENESS ANALYSIS OF ENTECAVIR (BARACLUDE) IN TURKEY

    Nov 1, 2010, 00:00

  • PMC13 METHODS AND IMPACT OF INCORPORATING MEDICATION COMPLIANCE INTO PHARMACOECONOMIC EVALUATIONS

    Nov 1, 2010, 00:00

  • PIN63 PATIENT PREFERENCES FOR BENEFITS, RISKS, AND WEIGHT OF EVIDENCE ASSOCIATED WITH HEPATITIS B TREATMENTS

    Nov 1, 2010, 00:00

  • PMH38 A COST UTILITY ANALYSIS OF FIRST LINE ANTIPSYCHOTICS FOR THE PREVENTION OF SCHIZOPHRENIA RELAPSE IN THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PIN47 COST-EFFECTIVENESS ANALYSIS OF PNEUMOCOCCAL VACCINES IN TAIWAN

    Nov 1, 2010, 00:00

  • PCN27 ESTIMATION OF THE EPIDEMIOLOGICAL EFFECT OF TRASTUZUMAB OVER THE 200-2015 PERIOD IN PORTUGAL

    Nov 1, 2010, 00:00

  • PDB28 THE EFFECT OF METFORMIN BRAND SHIFT BY HOSPITAL ON ANTIDIABETICS UTILIZATION

    Nov 1, 2010, 00:00

  • PCV16 THE EFFECT OF SITAXENTAN ON EXERCISE CAPACITY, HEMODYNAMIC FUNCTION, AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2010, 00:00

  • PCN5 EFFICACY OF PALONOSETRON (PAL) COMPARED TO OTHER SEROTONIN INHIBITORS (5-HT3R) IN PREVENTING CHEMOTHERAPYINDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT- AN UPDATE OF THE PREVIO ...

    Nov 1, 2010, 00:00

  • PMC38 A COGNITIVE DEBRIEFING METHODOLOGY FOR ESTABLISHING EQUIVALENCE DURING E-PRO MIGRATION

    Nov 1, 2010, 00:00

  • PCN129 A DATABASE REVIEW OF PATIENT-REPORTED OUTCOME STUDIES IN EORTC CANCER CLINICAL TRIALS

    Nov 1, 2010, 00:00

  • PGI25 CHILD AND PARENT REPORTS OF SYMPTOMS OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)- RESULTS OF QUALITATIVE INTERVIEWS

    Nov 1, 2010, 00:00

  • PMS2 GASTROINTESTINAL AND CARDIOVASCULAR RISK OF NONSELECTIVE NSAIDS AND COX-2 INHIBITORS IN ELDERLY PATIENTS WITH KNEE OSTEOARTHRITIS

    Nov 1, 2010, 00:00

  • IN1 ECONOMIC AND CLINICAL BURDEN OF PNEUMOCOCCAL DISEASES AND ACUTE OTITIS MEDIA IN TAIWAN- A NATIONWIDE POPULATION-BASED DATABASE ANALYSIS

    Nov 1, 2010, 00:00

  • PDB29 COST OF DIABETES MELLITUS TYPE 1 AND 2 STUDIES IN COUNTRIES OF CENTRAL AND EASTERN EUROPE-A SYSTEMATIC REVIEW OF THE LITARATURE

    Nov 1, 2010, 00:00

  • PCV19 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL HIP AND KNEE REPLACEMENT (THR, TKR) IN CHINESE PATIENTS

    Nov 1, 2010, 00:00

  • PDB63 LIRAGLUTIDE IN THE TREATMENT OF TYPE 2 DIABETES MIELLITUS-ECONOMIC EVALUATION IN ROMANIAN SETTING

    Nov 1, 2010, 00:00

  • PDB83 TIME TO TREATMENT MODIFICATION AMONG PATIENTS WITH TYPE 2 DIABETES WHO INITIATED EXENATIDE OR INSULIN GLARGINE

    Nov 1, 2010, 00:00

  • PSS2 COMPARISON OF COSTING METHODS- COST TO CHARGE RATIO AND DIAGNOSIS RELATED GROUP USING STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS AS A CASE STUDY

    Nov 1, 2010, 00:00

  • PDB25 RELATIONSHIPS OF QUALITY OF LIFE AND COSTS WITH CLINICAL CHARACTERISTICS OF DIABETES PATIENTS

    Nov 1, 2010, 00:00

  • PIH5 MEDICAL COST AND UTILIZATION FOR PATIENTS WITH POSTPARTUM HEMORRHAGE IN KOREA

    Nov 1, 2010, 00:00

  • PCN35 PRIMARY HEPATOCELLULAR CARCINOMA PATIENTS REPEATED MEDICAL UTILIZATION AND EXPENDITURE FOR CONFIRMATION IN TAIWAN

    Nov 1, 2010, 00:00

  • PIH21 QUALITY OF LIFE IMPACT IN PARENTS CARING FOR SEVERE GASTROENTERITIS IN CHILDREN IN SEVEN COUNTRIES WORLDWIDE

    Nov 1, 2010, 00:00

  • PSY63 WORK AND DAILY ACTIVITY IMPAIRMENT IN PATIENTS WITH DIGITAL ULCERS (DUS)-RESULTS FROM THE DUO REGISTRY

    Nov 1, 2010, 00:00

  • PHP4 EFFECTIVENESS OF TWO POLICIES TO REDUCE DIPHENOXYLATE CONSUMPTION IN IRAN

    Nov 1, 2010, 00:00

  • PCN30 ESTIMATING WOMENS PREFERENCES FOR CERVICAL CANCER SCREENING PROGRAMS USING CONJOINT ANALYSIS

    Nov 1, 2010, 00:00

  • PDB74 TYPE 2 DIABETES PATIENT PERSPECTIVES ON HYPOGLYCEMIA

    Nov 1, 2010, 00:00

  • PSY39 REAL-WORLD COST-EFFECTIVENESS OF BORTEZOMIB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PIH22 DO LOW-INCOME GROUPS IN PAKISTAN UNDERSTAND THE CONCEPT OF GENERIC MEDICINES?

    Nov 1, 2010, 00:00

  • PCN105 COST SAVINGS ASSOCIATED WITH BEVACIZUMAB-BASED THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

    Nov 1, 2010, 00:00

  • PSS11 THE COST-EFFECTIVENESS OF A NEW GEL FORMULATION OF CALCIPOTRIOL/BETAMETHASONE DIPROPIONATE FOR THE TREATMENT OF SCALP PSORIASIS IN NORWAY

    Nov 1, 2010, 00:00

  • PUK28 THE ECONOMIC BURDEN OF POST-TRANSPLANT EVENTS IN RENAL TRANSPLANT PATIENTS (PORTRAIT STUDY) IN A SINGLE UK CENTRE

    Nov 1, 2010, 00:00

  • PGI10 MODELLING THE IMPACT OF TREATMENT WITH ENTECAVIR ON HEALTH CARE COSTS OF CHRONIC HEPATITIS B IN FRANCE

    Nov 1, 2010, 00:00

  • PMS34 COST-EFFECTIVENESS OF GOLIMUMAB IN PSORIATIC ARTHRITIS FROM THE UK PAYER PERSPECTIVE

    Nov 1, 2010, 00:00

  • PHP83 EFFECTS OF COST-CONTAINMENT METHODS TO DRUG PRICE LEVEL IN EUROPE

    Nov 1, 2010, 00:00

  • PCV86 ECONOMIC EVALUATION OF DRONEDARONE IN TREATMENT OF ATRIAL FIBRILLATION IN GREECE

    Nov 1, 2010, 00:00

  • PCV29 DESIGN OF A DISCRETE CHOICE EXPERIMENT TO QUANTIFY CONSUMER PREFERENCES FOR CHRONIC HEART FAILURE MANAGEMENT PROGRAMS

    Nov 1, 2010, 00:00

  • EQ3 ESTIMATING THE SF-6D VALUE SET FOR A POPULATION BASED SAMPLE OF BRAZILIANS

    Nov 1, 2010, 00:00

  • PSY35 THE COST-EFFECTIVENESS OF DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN THE UNITED STATES

    Nov 1, 2010, 00:00

  • PCN20 COST-EFFECTIVENESS ANALYSIS OF A FOBT-BASED COLORECTAL CANCER SCREENING PROGRAM

    Nov 1, 2010, 00:00

  • PHP91 REGIONAL DIFFERENCES IN NUMBER OF PSYCHIATRIC BEDS IN HUNGARY FOLLOWING THE 2007 HEALTH CARE REFORM IN HUNGARY

    Nov 1, 2010, 00:00

  • PMS59 THE EFFECT OF TNF THERAPY, SOCIODEMOGRAPHIC AND CLINICAL FACTORS ON SLEEP DISTURBANCES AND FATIGUE AMONG RHEUMATOID ARTHRITIS-RESULTS FROM THE NDB-PORTUGAL COHORT

    Nov 1, 2010, 00:00

  • CE3 COST-UTILITY ANALYSIS OF CHOLINESTERASE INHIBITORS IN THE TREATMENT OF MILD TO MODERATE ALZHEIMERS DISEASE

    Nov 1, 2010, 00:00

  • PMS9 TREND OF HIP FRACTURE INCIDENCE IN BELGIUM BETWEEN 2000 AND 2007 AND FUTURE PROJECTIONS

    Nov 1, 2010, 00:00

  • PCN40 COST ANALYSIS OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN PORTUGAL- A COMPARISON OF BEVACIZUMAB IN COMBINATION WITH INTERFERON ALFA-2A AND SUNITINIB

    Nov 1, 2010, 00:00

  • PCV31 BASELINE HEALTH-RELATED QUALITY OF LIFE STUDY IN HONG KONG CARDIAC PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

    Nov 1, 2010, 00:00

  • PMC54 TREATMENT SATISFACTION INSTRUMENTS FOR DIFFERENT PURPOSES DURING A PRODUCTS LIFECYCLE-KEEPING THE END IN MIND

    Nov 1, 2010, 00:00

  • PDB77 QUALITY OF TREATMENT OF DIABETES MELLITUS TYPE 2 IN THE CZECH REPUBLIC

    Nov 1, 2010, 00:00

  • PIH33 COMMUNITY PHARMACIST PERCEPTION TOWARD THEIR ROLE IN HEALTH-CARE SYSTEM OF PAKISTAN- A QUANTITATIVE ASSESSMENT

    Nov 1, 2010, 00:00

  • PCN107 FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB AND SOCIETAL COST SAVINGS IN SPAIN

    Nov 1, 2010, 00:00

  • PDB55 COMPARISON OF RESOURCE USE AND COSTS IN TYPE 1 DIABETES PATIENTS TREATED WITH DIFFERENT LONG ACTING INSULINS IN A BASAL-BOLUS REGIMEN IN GERMANY

    Nov 1, 2010, 00:00

  • CV3 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM (VTE) AFTER TOTAL KNEE REPLACEMENT (TKR) IN CHINA

    Nov 1, 2010, 00:00

  • PCN15 COST ANALYSIS BETWEEN TYROSINE KINASE INHIBITOR VERSUS DOCETAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER

    Nov 1, 2010, 00:00

  • NI3 NICES COST-EFFECTIVENESS THRESHOLD REVISITED- NEW EVIDENCE ON THE INFLUENCE OF COST-EFFECTIVENESS AND OTHER FACTORS ON NICE DECISIONS

    Nov 1, 2010, 00:00

  • PSY57 WILLINGNESS TO PAY FOR OBESITY PHARMACOLOGY

    Nov 1, 2010, 00:00

  • PCN54 HOSPITAL UNDERTAKING OF PATIENTS WITH A RESECTION OF LUNG TUMOR IN FRANCE

    Nov 1, 2010, 00:00

  • PDB47 THE COST-EFFECTIVENESS OF CONTINUOUS GLUCOSE MONITORING IN TYPE 1 DIABETES PATIENTS IN THE NETHERLANDS

    Nov 1, 2010, 00:00

  • PCV40 WHICH STRATEGY CAN CONTROL THE EXPENDITURE OF HIGH-PRICE DRUGS?

    Nov 1, 2010, 00:00

  • PRS3 COMORBIDITY PROFILING OF COPD PATIENTS IN THE UNITED KINGDOM PRIMARY CARE USING AN INCIDENCE BASED APPROACH TO DETECT ASSOCIATIONS WITH THE DISEASE

    Nov 1, 2010, 00:00

  • PUK14 HEALTH CARE COST OF RENAL REPLACEMENT THERAPY IN HUNGARY

    Nov 1, 2010, 00:00

  • PHP67 HAS THE QUALITY AND OUTCOMES FRAMEWORK INFLUENCED PRIMARY CARE DATA RECORDING?

    Nov 1, 2010, 00:00

  • A Multimarker Approach for the Prediction of Coronary Artery Disease- Cost-Effectiveness Analysis

    Sep 1, 2010, 00:00

  • Quantification of the Potential Impact of Cost-effectiveness Thresholds on Dutch Drug Expenditures Using Retrospective Analysis

    Sep 1, 2010, 00:00

  • Medical Services Utilization and Expenditure of Obesity-Related Disorders in Taiwanese Adults

    Sep 1, 2010, 00:00

  • Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis

    Sep 1, 2010, 00:00

  • An Ounce of Prevention Is Worth a Pound of Cure- A Cost-Effectiveness Analysis of Incidentally Detected Aneurysms in Functional MRI Research

    Sep 1, 2010, 00:00

  • Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada

    Sep 1, 2010, 00:00

  • Cost-Effectiveness of Therapeutic Hypothermia to Treat Neonatal Encephalopathy

    Sep 1, 2010, 00:00

  • The Impact of Value-Based Benefit Design on Adherence to Diabetes Medications- A Propensity Score-Weighted Difference in Difference Evaluation

    Sep 1, 2010, 00:00

  • Persistence Patterns with Oral Antidiabetes Drug Treatment in Newly Treated Patients—A Population-Based Study

    Sep 1, 2010, 00:00

  • Health Technology Assessment and Economic Evaluation across Jurisdictions

    Sep 1, 2010, 00:00

  • A Competing Risks Prescription Refill Model of Compliance and Persistence

    Sep 1, 2010, 00:00

  • Clustering Rasch Results- A Novel Method for Developing Rheumatoid Arthritis States for Use in Valuation Studies

    Sep 1, 2010, 00:00

  • Evaluating Willingness-to-Pay Thresholds for Dementia Caregiving Interventions- Application to the Tailored Activity Program

    Sep 1, 2010, 00:00

  • Differences in Child versus Parent Reports of the Child's Health-Related Quality of Life in Children with Epilepsy and Healthy Siblings

    Sep 1, 2010, 00:00

  • Willingness to Pay for Lung Cancer Treatment

    Sep 1, 2010, 00:00

  • Health Technology Assessment and Economic Evaluation- Arguments for a National Approach

    Sep 1, 2010, 00:00

  • The Unit Costs of Inpatient Hospital Days, Outpatient Visits, and Daycare Treatments in the Fields of Oncology and Hematology

    Sep 1, 2010, 00:00

  • Measuring Patient Anxiety in Primary Care- Rasch Analysis of the 6-item Spielberger State Anxiety Scale

    Sep 1, 2010, 00:00

  • How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma

    Sep 1, 2010, 00:00

  • The Cost-Effectiveness of Spinal Cord Stimulation for Complex Regional Pain Syndrome

    Sep 1, 2010, 00:00

  • Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom- Findings from the INFORCE Study

    Sep 1, 2010, 00:00

  • Modeling the Long-Term Cost-Effectiveness of the Caries Management System in an Australian Population

    Sep 1, 2010, 00:00

  • The Modeled Lifetime Cost-Effectiveness of Published Adherence-Improving Interventions for Antihypertensive and Lipid-Lowering Medications

    Sep 1, 2010, 00:00

  • A Cost-Utility Analysis of Microwave Endometrial Ablation versus Thermal Balloon Endometrial Ablation

    Jul 1, 2010, 00:00

  • Cost-Effectiveness of Duloxetine- The Stress Urinary Incontinence Treatment (SUIT) Study

    Jul 1, 2010, 00:00

  • A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group

    Jul 1, 2010, 00:00

  • General Population Reference Values for the French Version of the EuroQol EQ-5D Health Utility Instrument

    Jul 1, 2010, 00:00

  • Early-Stage Valuation of Medical Devices- The Role of Developmental Uncertainty

    Jul 1, 2010, 00:00

  • Projecting the Effect of Nesiritide on Dialysis and Hospital Mortality in Cardiac Surgery Patients

    Jul 1, 2010, 00:00

  • Validation and Comparison of EuroQol and Short Form 6D in Chronic Prostatitis Patients

    Jul 1, 2010, 00:00

  • Small Budget Impact Is a Result of Flawed Assumptions and Ignores Questionable Cost-Effectiveness for RSV Prophylaxis

    Jul 1, 2010, 00:00

  • Populating an Economic Model with Health State Utility Values- Moving toward Better Practice

    Jul 1, 2010, 00:00

  • Evaluating Interventions to Improve Antiretroviral Adherence- How Much of an Effect Is Required for Favorable Value?

    Jul 1, 2010, 00:00

  • Constructing a Conceptual Framework of Patient-Reported Outcomes for Metastatic Hormone-Refractory Prostate Cancer

    Jul 1, 2010, 00:00

  • The Cost-Effectiveness of Group Cognitive Behavioral Therapy Compared with Routine Primary Care for Women with Postnatal Depression in the UK

    Jul 1, 2010, 00:00

  • Empirically Evaluating Decision-Analytic Models

    Jul 1, 2010, 00:00

  • Abolition of Prescription Copayments in Wales- An Observational Study on Dispensing Rates

    Jul 1, 2010, 00:00

  • Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China- A Markov Analysis

    Jul 1, 2010, 00:00

  • A Valuation of Infusion Therapy to Preserve Islet Function in Type 1 Diabetes

    Jul 1, 2010, 00:00

  • Eliciting Distributions to Populate Decision Analytic Models

    Jul 1, 2010, 00:00

  • Cost–Utility Analysis of Topical Intranasal Steroids for Otitis Media with Effusion Based on Evidence from the GNOME Trial

    Jul 1, 2010, 00:00

  • The Transferability of Valuing Lost Productivity across Jurisdictions. Differences between National Pharmacoeconomic Guidelines

    Jul 1, 2010, 00:00

  • A Portuguese Value Set for the SF-6D

    Jul 1, 2010, 00:00

  • Consequences of Screening in Lung Cancer- Development and Dimensionality of a Questionnaire

    Jul 1, 2010, 00:00

  • Network Meta-Analysis- Importance of Appropriate Trial Selection

    Jul 1, 2010, 00:00

  • Incorporating Equity–Efficiency Interactions in Cost-Effectiveness Analysis—Three Approaches Applied to Breast Cancer Control

    Jul 1, 2010, 00:00

  • Assessing the Economic Value of Public Health Programs Based on Risk- The Case of the Cancer Plan in France

    Jul 1, 2010, 00:00

  • Response to Comments on “No Study Left Behind- A Network Meta-Analysis in Non–Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data”

    Jul 1, 2010, 00:00

  • Tutorial in Medical Decision Modeling Incorporating Waiting Lines and Queues Using Discrete Event Simulation

    Jun 1, 2010, 00:00

  • Net Clinical Benefit- The Art and Science of Jointly Estimating Benefits and Risks of Medical Treatment

    Jun 1, 2010, 00:00

  • Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization

    Jun 1, 2010, 00:00

  • Cost–Effectiveness of Osteoporosis Screening Followed by Treatment- The Impact of Medication Adherence

    Jun 1, 2010, 00:00

  • An Evaluation of the Cost-Effectiveness of Rituximab in Combination with Chemotherapy for the First-Line Treatment of Follicular Non-Hodgkin's Lymphoma in the UK

    Jun 1, 2010, 00:00

  • Patient Expectations and Health-Related Quality of Life Outcomes Following Total Joint Replacement

    Jun 1, 2010, 00:00

  • Transportability of Comparative Effectiveness and Cost-Effectiveness between Countries

    Jun 1, 2010, 00:00

  • Effects of Method of Translation of Patient-Reported Health Outcome Questionnaires- A Randomized Study of the Translation of the Rheumatoid Arthritis Quality of Life (RAQoL) Instrument for Sweden

    Jun 1, 2010, 00:00

  • Conditionally Funded Field Evaluations- PATHs Coverage with Evidence Development Program for Ontario

    Jun 1, 2010, 00:00

  • Experimental and Observational Data and Formulary Listing

    Jun 1, 2010, 00:00

  • Social Time Preferences for Health and Money Elicited with a Choice Experiment

    Jun 1, 2010, 00:00

  • Bayesian Analysis of Nosocomial Infection Risk and Length of Stay in a Department of General and Digestive Surgery

    Jun 1, 2010, 00:00

  • International Development of the Unidimensional Fatigue Impact Scale (U-FIS)

    Jun 1, 2010, 00:00

  • Health Technology Assessment and Comparative Effectiveness in Sweden

    Jun 1, 2010, 00:00

  • Quantifying Women's Stated Benefit–Risk Trade-Off Preferences for IBS Treatment Outcomes

    Jun 1, 2010, 00:00

  • Dimensionality and Summary Measures of the SF-36 v1.6- Comparison of Scale- and Item-Based Approach Across ECRHS II Adults Population

    Jun 1, 2010, 00:00

  • Distributions of Parameters for Uncertainty Analysis Cannot Be Defined without Using Prior Information

    Jun 1, 2010, 00:00

  • Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the US and Other Countries

    Jun 1, 2010, 00:00

  • Factors Influencing Cost-Related Nonadherence to Medication in Older Adults- A Conceptually Based Approach

    Jun 1, 2010, 00:00

  • Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1- Are Tobit and CLAD Models Appropriate?

    Jun 1, 2010, 00:00

  • Impact of Waist Circumference Difference on Health-Care Cost among Overweight and Obese Subjects- The PROCEED Cohort

    Jun 1, 2010, 00:00

  • Treatment Patterns and Adherence among Patients with Chronic Hepatitis C Virus in a US Managed Care Population

    Jun 1, 2010, 00:00

  • Application of the Disease-Specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Questionnaire in a General Population- Results from a French Panel Study

    Jun 1, 2010, 00:00

  • Editorial

    Jun 1, 2010, 00:00

  • The Effect Size in Uncertainty Analysis

    Jun 1, 2010, 00:00

  • Response to- A Methodology for Successfully Producing Global Translations of Patient-Reported Outcomes Measures for Use in Multiple Countries by Two et al.

    Jun 1, 2010, 00:00
  • «
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137 (current)
  • 138
  • 139
  • 140
  • »